{
  "report_rows": [
    {
      "kpi": "Adjusted diluted EPS",
      "prediction": "BEAT",
      "answer": "pred ~$0.33 vs. cons $0.32",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Net sales",
      "prediction": "IN-LINE",
      "answer": "pred ~$4.00B vs. cons $3.99B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Organic sales growth",
      "prediction": "BEAT",
      "answer": "pred ~1.6% vs. cons 0.8%",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "Kimberly-Clark transaction consideration",
      "prediction": "UNCHANGED",
      "answer": "guide ~$3.50 cash + 0.14625 KMB shares vs. cons $3.50 cash + 0.14625 KMB shares (H2 2026)",
      "confidence": "HIGH"
    },
    {
      "kpi": "Merger closing timing / regulatory-status commentary",
      "prediction": "UNCHANGED",
      "answer": "guide ~6 months remaining to H2 2026 close vs. cons 6 months remaining to H2 2026 close (H2 2026)",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": 0.4,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 0.2,
  "day5_path": "STABILIZE",
  "day5_rationale": "A modest ~$0.01 EPS beat and ~0.8-point organic-sales upside support the operating narrative, but unchanged merger terms and timing leave little scope for estimate revisions or deal-spread compression; residual return ~0.2% versus day-1 residual ~0.4%.",
  "day5_confidence": "MEDIUM"
}